
TSE:MFC
This summary was created by AI, based on 28 opinions in the last 12 months.
Manulife Financial (MFC) has been viewed as a stable income stock with a healthy dividend yield, making it attractive for long-term investors. Despite some concerns over short-term earnings performance, particularly in U.S. operations, many analysts see potential in its growth in Asia and wealth management segments. The company is considered well-capitalized, and its valuation is generally viewed as reasonable compared to Canadian banks, although some experts express caution due to the slow growth typical of the life insurance market. The recent pullbacks in stock price may provide entry points for investors, and while there are mixed sentiments, MFC is likely to continue benefiting from aging demographics and investment opportunities in emerging markets. Overall, the stock is supported by a solid dividend, and investors are advised to watch for strategic developments and market conditions before making new investments.
He likes trading sideways stocks, as long as you know the downside potential. He recently bought MFC off the mid-$20's bounce, and he believes it could teach the mid-high-$20's. Not a huge trade, but pays a good dividend. It could reach that peak in the winter. And it's not a high-risk play. (3.7% dividend, Analysts' price target: $30.03)
He owned it going into the financial crisis and bailed out because it was overleveraged to markets and was unhedged. After it was hurt by this, it overreacted and is now so well hedged that it cannot benefit from rising interest rates. He likes the life insurance industry and owns three companies in that space, but not this one. Among Canadian insurers, he prefers Sun Life. He thinks it is better managed, with better exposure to interest rates. He likes the international diversification of both Manulife and Sun Life, but Manulife’s biggest international diversification is via John Hancock in the US, which is troubled.
This is one of the few Canadian companies he owns. He likes it. He likes the potential of the business, and the leverage to higher rates. The stock rose in expectation of higher rates and dropped off when the main increases were postponed. The company struggled with its US business, but now the company is stronger, the dividend is fine and will gradually increase. Eventually the Asian expansion will pay off and the stock will probably move to the low $30’s, which is where many people have set a target price. He would nibble away at it at this price. He would buy a lot more at $20 and would sell some at $32.
(A Top Pick October 23, 2017. Down 6%) All insurers are suffering from the yield curve (the low difference between short-term and long-term rates). The worst is over for the entire sector. Manulife should have 10% earnings growth over the next 10 years even with the current environment. He likes the insurance sector generally and he likes the US and Asian exposure of Manulife.
A primary holding for him. He really likes it. They've exceeded analyst expectations over several quarters, but the new CEO is dealing with long-term care and John Hancock, legacy businesses in the U.S. Meanwhile, Asia its business is rapidly growing. It's been in the woodshed for a while, but in time, investors will recognize its value. It is very competitively priced now.
It's gone nowhere in the last year, but up 25% in the past five. Earnings growth is good. New management's focus is on wealth management and Asia. Yes, John Hancock is a legacy they continue to deal with, but MFC's operational side is doing fairly well and its Asian operations are gangbusters, showing impressive growth.